Type 2 diabetes treatments to date have focused on managing the symptoms of the disease. Because type 2 diabetes is a progressive condition, treating the symptoms of the disease alone does not prevent the disease from worsening, thereby requiring more treatments to be added over time.
We believe that fundamentally new therapeutic approaches are needed to address the root cause of type 2 diabetes, insulin resistance, in a way that is durable and effective in the real world, not just in the clinical lab.
With our patients’ long-term wellbeing as our North Star, we are dedicated to developing therapies that contribute to better metabolic health rather than more disease management.
Only 50 percent of type 2 diabetes patients who use insulin are well-controlled, that is, at their target blood sugar level. For people with advanced type 2 diabetes who have inadequate control of their disease and yet are already on long-acting insulin therapy, the only treatment option available today is insulin dose escalation. But higher insulin dosages have diminishing effects on blood sugar, and they bring greater risk of side effects, including hypoglycemia (dangerously low blood sugar) and weight gain. Higher insulin doses are associated with more morbidity and higher rates of hospitalization.
We are now enrolling people with type 2 diabetes who are uncontrolled on insulin therapy in the REVITA-T2Di (NCT #04419779) clinical research study. REVITA-T2Di will assess the potential of outpatient Revita® DMR treatment to improve blood sugar control and help to eliminate patients’ need for daily insulin.
REVITA-T2Di is a prospective, randomized, double-blind, sham-controlled study that is expected to enroll more than 300 patients at up to 35 sites in the United States and Europe.
To learn more about the study and determine if you might be eligible to participate, visit revitastudy.com.